001630.KS
Strong BuyUnloved QualityAI neutralChong Kun Dang Holdings Corp. · Healthcare · South Korea · $132M
KRW 37,350 -0.3% · close 2 Oct · scored 6 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Chong Kun Dang Holdings is the holding company of a Korean pharmaceutical group making prescription drugs, pharmaceutical ingredients and consumer health products. It trades at a steep valuation discount, which is typical of Korean holding companies. There is no recent news pointing to a catalyst that would close that gap.
ABOUT CHONG KUN DANG HOLDINGS CORP.
Read
Chong Kun Dang Holdings Corp. is a pharmaceutical holding company involved in the research, development, manufacturing, and marketing of ethical drugs, OTC medications, and health functional foods. The company benefits from a diversified product portfolio, robust R&D pipeline, and strong brand reputation in the South Korean pharmaceutical market. Chong Kun Dang is a major South Korean pharmaceutical group, demonstrating significant capabilities in both original drug development and the production of generic and biosimilar medicines.
FINANCIAL SUMMARY (KRW)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | 926.0B | 909.0B | 879.8B | 957.8B | 959.0B | 0.9% | 962.6B |
| EPS (KRW) | 3,212 | 219.00 | 9,744 | 7,057 | 8,493 | 27.5% | 8,501 |
| Shares | 5.0M | 4.9M | 4.8M | 4.8M | 4.8M | -5.0% | 4.8M |
| Debt | 345.3B | 429.3B | 468.0B | 479.7B | 540.8B | 11.9% | 603.5B |
| Equity | 541.0B | 528.9B | 563.0B | 587.5B | 637.0B | 4.2% | — |
| Op CF | 40.5B | -46.5B | 37.1B | 24.0B | 76.0B | 17.1% | 104.5B |
| Inv CF | -108.1B | -64.7B | -24.0B | -37.7B | -72.9B | — | — |
| Fin CF | 109.0B | 67.0B | -4.1B | -3.1B | 47.9B | — | — |
Calmer than 82% of stocks we rank over the past year (25% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 001630.KS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 001630.KS | Chong Kun Dang Holdings Corp.(you) | $132M | 86 | Strong Buy |
| 023910.KQ | Daihan Pharmaceutical Co.,Ltd. | $114M | 90 | Strong Buy |
| 008490.KS | Suheung Co., Ltd. | $163M | 82 | Strong Buy |
| 234080.KS | JW Lifescience Corporation | $126M | 94 | Strong Buy |
| 005500.KS | Samjin Pharmaceuticals Co., Ltd. | $172M | 90 | Strong Buy |
| 016580.KS | Whan In Pharm Co.,Ltd. | $137M | 94 | Strong Buy |
| 033270.KS | Korea United Pharm Inc. | $206M | 87 | Strong Buy |
| 106190.KQ | High Tech Pharm Co., Ltd. | $78M | 80 | Strong Buy |
| 243070.KQ | Huons Co., Ltd. | $162M | 73 | Buy |
| 072020.KQ | Choong Ang Vaccine Laboratory Co., Ltd. | $63M | 82 | Strong Buy |
Peer medians: ROE -0.3% · P/E 17.6x · Gross margin 43.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.